Pharmacogenomics and Multiple Sclerosis: Moving Toward Individualized Medicine


DOI: 10.1007/s11910-011-0211-1

Cite this article as:
Comabella, M. & Vandenbroeck, K. Curr Neurol Neurosci Rep (2011) 11: 484. doi:10.1007/s11910-011-0211-1


Notwithstanding the availability of disease-modifying treatments including interferon-β, glatiramer acetate, and natalizumab, a considerable proportion of multiple sclerosis (MS) patients experience continued progression of disease, clinical relapses, disease activity on MRI, and adverse effects. Application of gene expression, proteomic or genomic approaches is universally accepted as a suitable strategy toward the identification of biomarkers with predictive value for beneficial/poor clinical response to therapy and treatment risks. This review focuses on recent progress in research on the pharmacogenomics of disease-modifying therapies for MS. Although MS drug response biomarkers are not yet routinely implemented in the clinic, the diversity of reported, promising molecular markers is rapidly increasing. Even though most of these markers await further validation, given time, this research is likely to empower neurologists with an enhanced armamentarium to facilitate rational decisions on therapy and patient management.


Multiple sclerosis Interferon-β Glatiramer acetate Natalizumab Single nucleotide polymorphism Biomarker Genomic Proteomic Drug response Pharmacogenomics Individualized medicine 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Centre d’Esclerosi Múltiple de Catalunya, CEM-Cat, Unitat de Neuroimmunologia ClínicaHospital Universitari Vall d’HebronBarcelonaSpain
  2. 2.Neurogenomiks Laboratory, Department of NeuroscienceUniversity of the Basque Country UPV/EHULeioaSpain
  3. 3.IKERBASQUEBasque Foundation for ScienceBilbaoSpain
  4. 4.Neurogenomiks, Dpto de NeurocienciasUniversidad del País Vasco UPV/EHU, Parque Tecnológico de BizkaiaZamudioSpain

Personalised recommendations